GSK’s Altabax Clears FDA As Topical Antibacterial
This article was originally published in The Pink Sheet Daily
Executive Summary
Ointment is approved for impetigo due to Staphylococcus aureus or Streptococcus pyogenes in patients nine months and older.
You may also be interested in...
GSK Signs Antibiotic Development Deal With Mpex
Research efforts will pair GSK marketed antibiotics and future candidates with Mpex’s efflux pump inhibitor technology.
GSK Signs Antibiotic Development Deal With Mpex
Research efforts will pair GSK marketed antibiotics and future candidates with Mpex’s efflux pump inhibitor technology.
GSK’s Altabax “Not Approvable” For Traumatic Lesions
FDA has revised its “approvable” decision from December and is now saying the secondarily infected traumatic lesions indication is “not approvable.”